Denali Therapeutics, Inc. (DNLI)
23.61
-0.39
(-1.62%)
USD |
NASDAQ |
Aug 31, 09:57
Denali Therapeutics Cash from Operations (Annual) : -412.60M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -412.60M |
| December 31, 2024 | -347.69M |
| December 31, 2023 | -357.99M |
| December 31, 2022 | -244.72M |
| December 31, 2021 | -211.39M |
| December 31, 2020 | 416.15M |
| Date | Value |
|---|---|
| December 31, 2019 | -151.58M |
| December 31, 2018 | 50.12M |
| December 31, 2017 | -76.64M |
| December 31, 2016 | -71.91M |
| December 31, 2015 | -14.97M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 179.55M |
| Oncolytics Biotech, Inc. | -20.11M |
| Sangamo Therapeutics, Inc. | -97.21M |
| Sarepta Therapeutics, Inc. | -222.54M |
| Anixa Biosciences, Inc. | -7.173M |